Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory,monoaminergic,antioxidant,immune-modulating and neuroprotective effects
Restricted accessResearch articleFirst published online December, 2012
Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory,monoaminergic,antioxidant,immune-modulating and neuroprotective effects
Curcumin is the principal curcuminoid of the popular Indian spice turmeric and has attracted increasing attention for the treatment of a range of conditions. Research into its potential as a treatment for depression is still in its infancy, although several potential antidepressant mechanisms of action have been identified. Research completed to date on the multiple effects of curcumin is reviewed in this paper, with a specific emphasis on the biological systems that are compromised in depression. The antidepressant effects of curcumin in animal models of depression are summarised, and its influence on neurotransmitters such as serotonin and dopamine is detailed. The effects of curcumin in moderating hypothalamus–pituitary–adrenal disturbances, lowering inflammation and protecting against oxidative stress, mitochondrial damage, neuroprogression and intestinal hyperpermeability, all of which are compromised in major depressive disorder, are also summarised. With increasing interest in natural treatments for depression, and efforts to enhance current treatment outcomes, curcumin is presented as a promising novel, adjunctive or stand-alone natural antidepressant.
AbbasiSHHosseiniFModabberniaA. (2012) Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled study. J Affect Disord. Epub ahead of print 19April2012. DOI: 10.1016/j.jad.2012.03.033.
2.
AbdipranotoAWuSStayteS. (2008) The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development. CNS Neurol Disord Drug Targets7: 187–210.
3.
AggarwalBBSungB (2009) Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmacol Sci30: 85–94.
4.
AkTGulcinI (2008) Antioxidant and radical scavenging properties of curcumin. Chem Biol Interact174: 27–37.
5.
AkhondzadehSJafariSRaisiF. (2009) Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety26: 607–611.
6.
AldertonWKCooperCEKnowlesRG (2001) Nitric oxide synthases: Structure, function and inhibition. Biochem J357: 593–615.
7.
AnandPKunnumakkaraABNewmanRA. (2007) Bioavailability of curcumin: Problems and promises. Mol Pharm4: 807–818.
8.
AntonyBMerinaBIyerS. (2008) A pilot cross-over study to evaluate human oral bioavailability of BCM-95 CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci70: 445–450.
BaranHStaniekKKepplingerB. (2003) Kynurenines and the respiratory parameters on rat heart mitochondria. Life Sci72: 1103–1115.
11.
BasnetPSkalko-BasnetN (2011) Curcumin: An anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules16: 4567–4598.
12.
BasuGDTinderTLBradleyJM. (2006) Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: Role of IDO. J Immunol177: 2391–2402.
13.
BelcaroGCesaroneMRDugallM. (2010) Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev15: 337–344.
14.
BereswillSMunozMFischerA. (2010) Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One5: e15099.
15.
BhatiaNJaggiASSinghN. (2011) Adaptogenic potential of curcumin in experimental chronic stress and chronic unpredictable stress-induced memory deficits and alterations in functional homeostasis. J Nat Med65: 532–543.
16.
BhutaniMKBishnoiMKulkarniSK (2009) Anti-depressant like effect of curcumin and its combination with piperine in unpredictable chronic stress-induced behavioral, biochemical and neurochemical changes. Pharmacol Biochem Behav92: 39–43.
17.
BishnoiMChopraKKulkarniSK (2008) Protective effect of curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav88: 511–522.
18.
BishnoiMChopraKRongzhuL. (2011) Protective effect of curcumin and its combination with piperine (bioavailability enhancer) against haloperidol-associated neurotoxicity: Cellular and neurochemical evidence. Neurotox Res20: 215–225.
19.
BraidyNGrantRAdamsS. (2010) Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J277: 368–382.
20.
BraidyNGuilleminGJGrantR (2011) Effects of kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res4: 29–37.
21.
CalabreseJRSkwererRGBarnaB. (1986) Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res17: 41–47.
22.
CarrGVLuckiI (2011) The role of serotonin receptor subtypes in treating depression: A review of animal studies. Psychopharmacology (Berl)213: 265–287.
23.
CesarioARoccaBRutellaS (2011) The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Curr Med Chem18: 2263–2271.
24.
ChandranBGoelA (2012) A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. Epub ahead of print 9March2012. DOI: 10.1002/ptr.4639.
25.
ChenYGuilleminGJ (2009) Kynurenine pathway metabolites in humans: Disease and healthy States. Int J Tryptophan Res2: 1–19.
26.
ChenYJiangTChenP. (2011) Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells. Psychiatry Res188: 224–230.
27.
ChimakurthyJTalasilaM (2010) Effects of curcumin on pentylenetetrazole-induced anxiety-like behaviors and associated changes in cognition and monoamine levels. Psychol Neurosci3: 239–244.
28.
CryanJFMombereauCVassoutA (2005) The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev29: 571–625.
29.
CumurcuBEOzyurtHEtikanI. (2009) Total antioxidant capacity and total oxidant status in patients with major depression: Impact of antidepressant treatment. Psychiatry Clin Neurosci63: 639–645.
30.
CuomoJAppendinoGDernAS. (2011) Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod74: 664–669.
31.
DantzerRO’ConnorJCLawsonMA. (2011) Inflammation-associated depression: From serotonin to kynurenine. Psychoneuroendocrinology36: 426–436.
32.
DhirAKulkarniSK (2011) Nitric oxide and major depression. Nitric Oxide24: 125–131.
33.
DobosNde VriesEFKemaIP. (2012) The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J Alzheimers Dis28: 905–915.
34.
DowlatiYHerrmannNSwardfagerW. (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry67: 446–457.
35.
DumanRS (2009) Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: Stress and depression. Dialogues Clin Neurosci11: 239–255.
36.
DumanRSMonteggiaLM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry59: 1116–1127.
37.
DunnAJ (2006) Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res6: 52–68.
38.
EyreHBauneBT (2012) Neuroplastic changes in depression: A role for the immune system. Psychoneuroendocrinology37: 1397–1416.
39.
FasanoAShea-DonohueT (2005) Mechanisms of disease: The role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol2: 416–422.
40.
FattalOLinkJQuinnK. (2007) Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr12: 429–438.
41.
ForlenzaMJMillerGE (2006) Increased serum levels of 8-hydroxy-2’-deoxyguanosine in clinical depression. Psychosom Med68: 1–7.
42.
FuXZunichSMO’ConnorJC. (2010) Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J Neuroinflammation7: 43.
43.
GaleckiPGaleckaEMaesM. (2012) The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord138: 360–366.
44.
GaoSFBaoAM (2011) Corticotropin-releasing hormone, glutamate, and gamma-aminobutyric acid in depression. Neuroscientist17: 124–144.
45.
GardnerABolesRG (2008a) Mitochondrial energy depletion in depression with somatization. Psychother Psychosom77: 127–129.
46.
GardnerABolesRG (2008b) Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. Biopsychosoc Med2: 7.
47.
GardnerABolesRG (2011) Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry35: 730–743.
48.
GardnerAJohanssonAWibomR. (2003) Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord76: 55–68.
49.
GilhotraNDhingraD (2010) GABAergic and nitriergic modulation by curcumin for its antianxiety-like activity in mice. Brain Res1352: 167–175.
50.
GoldPWChrousosGP (2002) Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs. low CRH/NE states. Mol Psychiatry7: 254–275.
51.
Government Medical College, Bhavnagar; Health and Family Welfare Department, Government of Gujarat, India; Arjuna Natural Extracts Ltd, Kerala, India (2012). A randomized, active controlled, open label, parallel group study to compare the efficacy of extract of curcuma longa (turmeric) with fluoxetine and to study its effect as an add on therapy to fluoxetine in patients of depression. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine, US. Available at: http://clinicaltrials.gov/ct2/show/NCT01022632. ClinicalTrials.gov NLM Identifier: NCT01022632 (accessed 17 August 2012).
52.
GrecoTFiskumG (2010) Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J Alzheimers Dis20: S427–437.
53.
GuptaSCPatchvaSKohW. (2012) Discovery of curcumin, a component of the golden spice, and its miraculous biological activities. Clin Exper Pharmacol Physiol39: 283–299.
54.
HannestadJDellaGioiaNBlochM (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: A meta-analysis. Neuropsychopharmacology36: 2452–2459.
HongJBoseMJuJ. (2004) Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: Effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis25: 1671–1679.
57.
HowrenMBLamkinDMSulsJ (2009) Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosom Med71: 171–186.
58.
HuangWTNiuKCChangCK. (2008) Curcumin inhibits the increase of glutamate, hydroxyl radicals and PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in rabbits. Eur J Pharmacol593: 105–111.
59.
HuangZZhongXMLiZY. (2011) Curcumin reverses corticosterone-induced depressive-like behavior and decrease in brain BDNF levels in rats. Neurosci Lett493: 145–148.
60.
JeongYIKimSWJungID. (2009) Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cdelta-STAT1 signaling pathway in interferon-gamma-stimulated murine dendritic cells. J Biol Chem284: 3700–3708.
61.
JiangHTianXGuoY. (2011) Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity. Biol Pharm Bull34: 1194–1197.
62.
JocaSRGuimaraesFS (2006) Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl)185: 298–305.
63.
JungIDJeongYILeeCM. (2010) COX-2 and PGE2 signaling is essential for the regulation of IDO expression by curcumin in murine bone marrow-derived dendritic cells. Int Immunopharmacol10: 760–768.
64.
JungKKLeeHSChoJY. (2006) Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci79: 2022–2031.
65.
KanakasabaiSCasaliniEWallineCC. (2012) Differential regulation of CD4(+) T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. J Nutr Biochem. Epub ahead of print 9March2012. DOI: 10.1016/j.jnutbio.2011.10.002.
66.
KaratepeOAcetEBattalM. (2010) Effects of glutamine and curcumin on bacterial translocation in jaundiced rats. World J Gastroenterol16: 4313–4320.
67.
KarolewiczBSzebeniKStockmeierCA. (2004) Low nNOS protein in the locus coeruleus in major depression. J Neurochem91: 1057–1066.
68.
KhajehdehiPPakfetratMJavidniaK. (2011) Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: A randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol45: 365–370.
69.
KhanzodeSDDakhaleGNKhanzodeSS. (2003) Oxidative damage and major depression: The potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep8: 365–370.
KoeneSKoziczTLRodenburgRJ. (2009) Major depression in adolescent children consecutively diagnosed with mitochondrial disorder. J Affect Disord114: 327–332.
72.
KulkarniSDhirAAkulaKK (2009) Potentials of curcumin as an antidepressant. ScientificWorldJournal9: 1233–1241.
73.
KulkarniSKDhirA (2010) An overview of curcumin in neurological disorders. Indian J Pharm Sci72: 149–154.
74.
KulkarniSKBhutaniMKBishnoiM (2008) Antidepressant activity of curcumin: Involvement of serotonin and dopamine system. Psychopharmacology (Berl)201: 435–442.
75.
KumarASinghA (2008) Possible nitric oxide modulation in protective effect of (Curcuma longa, Zingiberaceae) against sleep deprivation-induced behavioral alterations and oxidative damage in mice. Phytomedicine15: 577–586.
76.
LeeBHKimYK (2010) The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig7: 231–235.
LeeKHAbasFAlitheenNB. (2011) A curcumin derivative, 2,6-bis(2,5-dimethoxybenzylidene)-cyclohexanone (BDMC33) attenuates prostaglandin E2 synthesis via selective suppression of cyclooxygenase-2 in IFN-g/LPS-stimulated macrophages. Molecules16: 9728–9738.
79.
LeeSYChoiHKLeeKJ. (2009) The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother32: 22–28.
80.
LeonardBMaesM (2012) Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev36: 764–785.
81.
LiYCWangFMPanY. (2009) Antidepressant-like effects of curcumin on serotonergic receptor-coupled AC-cAMP pathway in chronic unpredictable mild stress of rats. Prog Neuropsychopharmacol Biol Psychiatry33: 435–449.
82.
LinTYLuCWWangCC. (2011) Curcumin inhibits glutamate release in nerve terminals from rat prefrontal cortex: possible relevance to its antidepressant mechanism. Prog Neuropsychopharmacol Biol Psychiatry35: 1785–1793.
83.
LinnoilaMWhortonARRubinowDR. (1983) CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry40: 405–406.
84.
LiuYHoRCMakA (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J Affect Disord139: 230–239.
85.
LoixSDe KockMHeninP (2011) The anti-inflammatory effects of ketamine: State of the art. Acta Anaesthesiol Belg62: 47–58.
86.
McBrideHMNeuspielMWasiakS (2006) Mitochondria: More than just a powerhouse. Curr Biol6: R551–R560.
87.
McEnteeWJCrookTH (1993) Glutamate: Its role in learning, memory, and the aging brain. Psychopharmacology (Berl)111: 391–401.
88.
McLeodTMLopez-FigueroaALLopez-FigueroaMO (2001) Nitric oxide, stress, and depression. Psychopharmacol Bull35: 24–41.
89.
McNallyLBhagwagarZHannestadJ (2008) Inflammation, glutamate, and glia in depression: A literature review. CNS Spectr13: 501–510.
90.
MaesM (2011) Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry35: 664–675.
91.
MaesMRiefW (2012) Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res196: 243–249.
92.
MaesMBerkMGoehlerL. (2012a) Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med10: 66.
93.
MaesMDe VosNPioliR. (2000) Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord58: 241–246.
94.
MaesMGaleckiPChangYS. (2011a) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry35: 676–692.
95.
MaesMGaleckiPVerkerkR. (2011b) Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett32: 264–273.
96.
MaesMKuberaMLeunisJC (2008a) The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett29: 117–124.
97.
MaesMKuberaMLeunisJC. (2012b) Increased IgA and IgM responses against gut commensals in chronic depression: Further evidence for increased bacterial translocation or leaky gut. J Affect Disord141: 55–62.
98.
MaesMLeonardBEMyintAM. (2011c) The new ‘5-HT’ hypothesis of depression: Cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry35: 702–721.
99.
MaesMMihaylovaIKuberaM. (2008b) An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS. Neuro Endocrinol Lett29: 313–319.
100.
MaesMMihaylovaIKuberaM. (2009a) Increased 8-hydroxy-deoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett30: 715–722.
101.
MaesMMihaylovaIKuberaM. (2009b) Lower plasma coenzyme Q10 in depression: A marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett30: 462–469.
102.
MaesMMihaylovaIKuberaM. (2011d) IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: New pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord135: 414–418.
103.
MaesMMihaylovaIKuberaM. (2011e) Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuro Endocrinol Lett32: 133–140.
104.
MaesMMihaylovaIRuyterMD. (2007) The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): Relevance for depression – and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett28: 826–831.
105.
MaesMScharpeSMeltzerHY. (1994) Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response. Psychiatry Res54: 143–160.
106.
MaesMYirmyiaRNorabergJ. (2009c) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis24: 27–53.
107.
MaesMZdenekFMedinaM. (2012c) New drug targets in depression: Inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates – Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology20: 127–150.
108.
MagalhaesPVDeanOMBushAI. (2011) N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr33: 374–378.
109.
MaleticVRobinsonMOakesT. (2007) Neurobiology of depression: An integrated view of key findings. Int J Clin Pract61: 2030–2040.
110.
ManikandanRBeulajaMThiagarajanR. (2011) Ameliorative effects of curcumin against renal injuries mediated by inducible nitric oxide synthase and nuclear factor kappa B during gentamicin-induced toxicity in Wistar rats. Eur J Pharmacol670: 578–585.
111.
ManjiHKDrevetsWCCharneyDS (2001) The cellular neurobiology of depression. Nat Med7: 541–547.
112.
MartinowichKLuB (2008) Interaction between BDNF and serotonin: Role in mood disorders. Neuropsychopharmacology33: 73–83.
113.
MartinowichKManjiHLuB (2007) New insights into BDNF function in depression and anxiety. Nat Neurosci10: 1089–1093.
114.
MathewSJShahALapidusK. (2012) Ketamine for treatment-resistant unipolar depression: Current evidence. CNS Drugs26: 189–204.
115.
MatthesSMosienkoVBashammakhS. (2010) Tryptophan hydroxylase as novel target for the treatment of depressive disorders. Pharmacology85: 95–109.
116.
MD Anderson Cancer Center (2012). Phase II Trial of Curcumin in Patients With Advanced Pancreatic Cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). Available at: http://clinicaltrials.gov/ct2/show/NCT00094445. ClinicalTrials.gov NLM Identifier: NCT00094445.
117.
MendlewiczJKriwinPOswaldP. (2006) Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: A pilot open-label study. Int Clin Psychopharmacol21: 227–231.
118.
MenonVPSudheerAR (2007) Antiinflammatory and anti-oxidant properties of curcumin. In: AggarwalBBSurhYJShishodiaS (eds) The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. New York: Springer.
119.
MeyerJHGinovartNBoovariwalaA. (2006) Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry63: 1209–1216.
120.
MillerAL (1997) The pathogenesis, clinical implications, and treatment of intestinal hyperpermeability. Alt Med Rev2: 330–345.
121.
MoriyukiKSekiguchiFMatsubaraK. (2010) Curcumin inhibits the proteinase-activated receptor-2-triggered prostaglandin E2 production by suppressing cyclooxygenase-2 upregulation and Akt-dependent activation of nuclear factor-κB in human lung epithelial cells. J Pharmacol Sci114: 225–229.
122.
MullerNSchwarzMJ (2008) COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des14: 1452–1465.
123.
MullerNSchwarzMJDehningS. (2006) The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry11: 680–684.
124.
MyintAM (2012) Kynurenines: From the perspective of major psychiatric disorders. FEBS J279: 1375–1385.
125.
MyintAMKimYKVerkerkR. (2007) Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord98: 143–151.
126.
MyintAMLeonardBESteinbuschHW. (2005) Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord88: 167–173.
127.
NagaharaAHTuszynskiMH (2011) Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov10: 209–219.
128.
NaikSRThakareVNPatilSR (2011) Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: Evidence of its antioxidant property. Exper Toxicol Pathol63: 419–431.
129.
NemeroffCBKrishnanKRReedD. (1992) Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gen Psychiatry49: 384–387.
130.
NgFBerkMDeanO. (2008) Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications. Int J Neuropsychopharmacol11: 851–876.
131.
O’ConnorJCLawsonMAAndreC. (2009) Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry14: 511–522.
132.
OhishiKUenoRNishinoS. (1988) Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry23: 326–334.
133.
OwenAJBatterhamMJProbstYC. (2005) Low plasma vitamin E levels in major depression: Diet or disease?Eur J Clin Nutr59: 304–306.
134.
OzcanMEGulecMOzerolE. (2004) Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol19: 89–95.
135.
ParianteCMLightmanSL (2008) The HPA axis in major depression: Classical theories and new developments. Trends Neurosci31: 464–468.
136.
Petit-DemouliereBChenuFBourinM (2005) Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology (Berl)177: 245–255.
137.
PieczenikSRNeustadtJ (2007) Mitochondrial dysfunction and molecular pathways of disease. Exper Mol Pathol83: 84–92.
138.
PintoVLBruniniTMFerrazMR. (2008) Depression and cardiovascular disease: Role of nitric oxide. Cardiovasc Hematol Agents Med Chem6: 142–149.
139.
PlummerSMHollowayKAMansonMM. (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene18: 6013–6020.
RaiBKaurJJacobsR. (2010) Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci52: 251–256.
142.
RaisonCLMillerAH (2011) Is depression an inflammatory disorder?Curr Psychiatry Rep13: 467–475.
143.
RaisonCLCapuronLMillerAH (2006) Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol27: 24–31.
144.
RaisonCLDantzerRKelleyKW. (2010) CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: Relationship to CNS immune responses and depression. Mol Psychiatry15: 393–403.
145.
RezinGTAmboniGZugnoAI. (2009) Mitochondrial dysfunction and psychiatric disorders. Neurochem Res34: 1021–1029.
146.
SanmukhaniJAnovadiyaATripathiCB (2011) Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: An acute and chronic study. Acta Pol Pharm68: 769–775.
147.
SarandolASarandolEEkerSS. (2007) Major depressive disorder is accompanied with oxidative stress: Short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol22: 67–73.
148.
ScapagniniGVastoSAbrahamNG. (2011) Modulation of Nrf2/ARE pathway by food polyphenols: A nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol44: 192–201.
149.
SenSDumanRSanacoraG (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry64: 527–532.
150.
ShaoLMartinMVWatsonSJ. (2008) Mitochondrial involvement in psychiatric disorders. Ann Med40: 281–295.
151.
ShihCALinJK (1993) Inhibition of 8-hydroxydeoxyguanosine formation by curcumin in mouse fibroblast cells. Carcinogenesis14: 709–712.
152.
ShobaGJoyDJosephT. (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med64: 353–356.
153.
SongCLeonardBE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev29: 627–647.
154.
SoodPKNaharUNehruB (2011) Curcumin attenuates aluminum-induced oxidative stress and mitochondrial dysfunction in rat brain. Neurotox Res20: 351–361.
155.
SrivastavaRMSinghSDubeySK. (2011) Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol11: 331–341.
156.
SteinerJWalterMGosT. (2011) Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission?J Neuroinflammation8: 94.
157.
SteruLChermatRThierryB. (1985) The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl)85: 367–370.
158.
StoneTWForrestCMDarlingtonLG (2012) Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J279: 1386–1397.
159.
SuzukiEYagiGNakakiT. (2001) Elevated plasma nitrate levels in depressive states. J Affect Disord63: 221–224.
160.
SzewczykBKuberaMNowakG (2011) The role of zinc in neurodegenerative inflammatory pathways in depression. Prog Neuropsychopharmacol Biol Psychiatry35: 693–701.
161.
TocharusJJamsuwanSTocharusC. (2012) Curcuminoid analogs inhibit nitric oxide production from LPS-activated microglial cells. J Nat Med66: 400–405.
162.
TokerLAmarSBersudskyY. (2010) The biology of tryptophan depletion and mood disorders. Isr J Psychiatry Relat Sci47: 46–55.
163.
University of California, Los Angeles (2012). Curcumin in rheumatoid arthritis – a cross-over pilot study. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine, US. Available from: http://clinicaltrials.gov/ct2/show/NCT00752154. ClinicalTrials.gov NLM Identifier: NCT00752154 (accessed 17 August 2012).
164.
UsharaniPMateenAANaiduMUR. (2008) Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus. Drugs R D9: 243–205.
165.
WangRXuYWuHL. (2008) The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol578: 43–50.
166.
WangYCuiXLLiuYF. (2011) LPS inhibits the effects of fluoxetine on depression-like behavior and hippocampal neurogenesis in rats. Prog Neuropsychopharmacol Biol Psychiatry35: 1831–1835.
167.
WardenDRushAJTrivediMH. (2007) The STAR*D Project results: A comprehensive review of findings. Curr Psychiatry Rep9: 449–459.
168.
WeiQYChenWFZhouB. (2006) Inhibition of lipid peroxidation and protein oxidation in rat liver mitochondria by curcumin and its analogues. Biochim Biophys Acta1760: 70–77.
169.
WeiYCZhouFLHeDL. (2009) The level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma. J Psychosom Res66: 259–266.
170.
WichersMCKoekGHRobaeysG. (2005) IDO and interferon-alpha-induced depressive symptoms: A shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry10: 538–544.
XiaXChengGPanY. (2007) Behavioral, neurochemical and neuroendocrine effects of the ethanolic extract from Curcuma longa L. in the mouse forced swimming test. J Ethnopharmacol110: 356–363.
173.
XieLLiXKFuneshima-FujiN. (2009) Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol9: 575–581.
174.
XuYKuBCuiL. (2007) Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. Brain Res1162: 9–18.
175.
XuYKuBSYaoHY. (2005a) Antidepressant effects of curcumin in the forced swim test and olfactory bulbectomy models of depression in rats. Pharmacol Biochem Behav82: 200–206.
176.
XuYKuBSYaoHY. (2005b) The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol518: 40–46.
177.
XuYLiSVernonMM. (2011) Curcumin prevents corticosterone-induced neurotoxicity and abnormalities of neuroplasticity via 5-HT receptor pathway. J Neurochem118: 784–795.
178.
YangCZhangXFanH. (2009) Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res1282: 133–141.
179.
YaronIShiraziIJudovichR. (1999) Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum42: 2561–2568.
180.
YirmiyaR (1996) Endotoxin produces a depressive-like episode in rats. Brain Res711: 163–174.
181.
YirmiyaRPollakYBarakO. (2001) Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology24: 531–544.
ZhangKSLiGCHeYW. (2008) Curcumin inhibiting the expression of indoleamine 2,3-dioxygenase induced by IFN-gamma in cancer cells. Zhong Yao Cai31: 1207–1211.
184.
ZhangMDengCSZhengJJ. (2006) Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin27: 1071–1077.
185.
ZhuYGChenXCChenZZ. (2004) Curcumin protects mitochondria from oxidative damage and attenuates apoptosis in cortical neurons. Acta Pharmacol Sin25: 1606–1612.
186.
ZunszainPAAnackerCCattaneoA. (2011) Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry35: 722–729.
